Related Experiment Video
Updated: Jun 28, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Effect of octreotide on postmenopausal hot flushes
Robert D Hoeldtke1, Kimberly D Bryner, Hugh C Palmer
1Department of Medicine, West Virginia University, Morgantown, WV, USA. hoeldtkerob@comcast.net
Octreotide therapy effectively reduces sweating and palpitations in patients experiencing postmenopausal hot flashes. This treatment also alleviates related symptoms, offering a new therapeutic avenue.
Area of Science:
- Endocrinology
- Gynecology
- Neurology
Background:
- Postmenopausal hot flashes are a common and distressing symptom impacting quality of life.
- Current treatments for hot flashes have limitations and potential side effects.
- Octreotide has previously shown efficacy in managing sweating and palpitations in postural tachycardia syndrome.
Purpose of the Study:
- To investigate the efficacy of octreotide in suppressing symptoms associated with postmenopausal hot flashes.
- To determine if octreotide's effects extend to symptoms beyond sweating and palpitations.
Main Methods:
- Observational study documenting patient-reported symptoms before and during octreotide therapy.
- Symptom assessment included sweating, palpitations, and other related vasomotor and autonomic disturbances.
- Data analysis focused on the reduction and suppression of reported symptoms.
Main Results:
- Octreotide therapy significantly suppressed sweating and palpitations in patients with postmenopausal hot flashes.
- Related symptoms, including other vasomotor and autonomic disturbances, were also alleviated.
- The findings suggest a broader application of octreotide in managing menopausal symptoms.
Conclusions:
- Octreotide is an effective treatment for suppressing key symptoms of postmenopausal hot flashes.
- The drug's mechanism may involve modulation of thermoregulatory and autonomic pathways.
- Further clinical trials are warranted to confirm these findings and establish optimal dosing and long-term safety.
Related Concept Videos
Menopause
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...